

Hammersmith Hospital, Imperial College London, UK. Thereafter, Dr. Sanders trained in internal medicine and nephrology at Medical Center Leeuwarden, Leeuwarden, The Netherlands, and at University Medical Center Groningen (UMCG). He combined this with a PhD trajectory, which he completed in 2009 with his thesis "Disease-activity in ANCA-associated Vasculitis." Since September 2010, he has been a staff member at the division of nephrology at UMCG, focusing on kidney transplantation and ANCA vasculitis. Since October 2019, he has served as the program director of the Kidney and Pancreas Transplantation Program at UMCG. His primary research interests are ANCA vasculitis and kidney transplantation. He has received research grants from the Dutch Kidney Society and the Netherlands Organisation for Health Research and Development.

*J-SFS declared no competing interests.*



**Vladimír Tesar, MD, PhD, FERA, FASN**, is head of the Department of Nephrology, 1<sup>st</sup> Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. He is a former member of the Executive Committee of the ISN, former chair of the Immunonephrology Working Group of ERA-EDTA, and a former member of the

council of ERA-EDTA. He is a member of the editorial board of the *Clinical Journal of the American Society of Nephrology*; *Nephrology Dialysis Transplantation*; and *Journal of Nephrology*, and former editor-in-chief of *Kidney and Blood Pressure Research*. His main interests are glomerular disease, inherited diseases of the kidney, and cardiovascular complications of chronic kidney disease (CKD). He participated in many genetic and biomarker studies in glomerular diseases and on the steering committees of many randomized, controlled (including investigator-initiated) clinical trials. He has co-authored more than 500 papers in international journals, mostly dedicated to glomerular disease.

*VT reports receiving funding for a leadership or fiduciary role at Calliditas, Novartis, Omeros, Otsuka, and Travere.*

#### KDIGO Chairs



**Michel Jadoul, MD**, received his MD degree in 1983 at the Université Catholique de Louvain (UCLouvain), Brussels, Belgium. Dr. Jadoul trained in internal medicine and nephrology under the mentorship of Professor Charles van Ypersele de Strihou. He has served as chair at the Department of Nephrology of the Cliniques Uni-

versitaires Saint-Luc (2003–2023) and is currently a full clinical professor at UCLouvain. Dr. Jadoul's clinical activities focus on the follow-up of hemodialysis and CKD patients, and his main research interests include  $\beta$ 2-

microglobulin amyloidosis, hepatitis C, and other complications (e.g., falls, bone fractures, sudden death) in hemodialysis patients, as well as cardiovascular complications after kidney transplantation and various causes of kidney disease (e.g., drug-induced).

Dr. Jadoul has coauthored over 350 scientific papers, most of them published in major nephrology journals. He is currently serving as an associate editor of *Nephrology Dialysis Transplantation*, and he is also a country co-investigator for the Dialysis Outcomes and Practice Patterns Study (DOPPS) (2001–present). In 2008, he received the International Distinguished Medal from the U.S. National Kidney Foundation (NKF). He was previously a member of the European Renal Association Council (2013–2016). Presently, Dr. Jadoul is a Kidney Disease: Improving Global Outcomes (KDIGO) Co-Chair.

*MJ reports receiving consultancy fees from Astellas\*, AstraZeneca\*, Bayer\*, Boehringer Ingelheim\*, Cardiorenal\*, CSL Vifor\*, Fresenius Medical Care Asia Pacific\*, GlaxoSmithKline\*, Mundipharma\*, and Vertex\*; grants/research support from Amgen and AstraZeneca\*; speaker honoraria from AstraZeneca\*, Bayer\*, and Boehringer Ingelheim\*; fees for providing expert testimony from Astellas\* and Stada-Euro-generics\*; travel support from AstraZeneca\*.*

*\*Monies paid to institution.*



**Morgan E. Grams, MD, PhD, MHS**, is the Co-Director of the New York University Division of Precision Medicine, a multidisciplinary research unit that aims to produce evidence to inform the delivery of high-quality, equitable patient care responding rapidly to changes in health care guidelines, delivery, safety, and regulation. A practicing nephrologist, PhD-trained epidemiologist, and the Susan and Morris Mark Professor of Medicine and Population Health at New York University, Dr. Grams is Co-Principal Investigator of the Chronic Kidney Disease Prognosis Consortium (CKD-PC), a consortium of over 30 million participants, 100 cohorts, and 250 investigators from around the globe. In this role, Dr. Grams and the CKD-PC team focus on developing, testing, and implementing analytic strategies to answer clinically meaningful questions using as much of the world's data on kidney measures and outcomes as possible. She also leads efforts to integrate multimodal omics data as they relate to kidney disease. She was the winner of the Young Investigator Award in 2018 given by the American Society of Nephrology/American Heart Association Kidney Council, the top award for investigators under 45 years of age, and she is a member of the American Society of Clinical Investigation. She attended medical school at Columbia University and completed her nephrology fellowship at Johns Hopkins University. She is also a Co-Chair of KDIGO.

*MG declared no competing interests.*